Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.58 |
| ▸ | TGM2 | P21980 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.55 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.55 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.54 |
| ▸ | HINT1 | P49773 | 3/20 | 0.53 |
| ▸ | RNASEL | Q05823 | 5/20 | 0.52 |
| ▸ | KRAS | P01116 | 3/20 | 0.51 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.51 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477429 | 0.91 | ADORA1 (0.67) | NT5ETGM2ADORA1HPGDTAS1R3 | |
| SCHEMBL2220159 | 0.91 | ADORA1 (0.67) | NT5ETGM2ADORA1HPGDTAS1R3 | |
| SCHEMBL31310507 | 0.91 | TAS1R3 (0.67) | NT5ETGM2TAS1R3TAS1R1FUT5 | |
| SCHEMBL18521471 | 0.90 | NT5E (0.55) | NT5ETGM2ADORA1HPGDTAS1R3 | |
| SCHEMBL27126358 | 0.88 | HPGD (0.58) | NT5ETGM2ADORA1HPGDTAS1R3 | |
| SCHEMBL18512866 | 0.88 | HPGD (0.61) | NT5ETGM2HPGDTAS1R3TAS1R1 | |
| SCHEMBL3713950 | 0.88 | HPGD (0.61) | NT5ETGM2HPGDTAS1R3TAS1R1 | |
| SCHEMBL16360143 | 0.88 | HPGD (0.61) | NT5ETGM2HPGDTAS1R3TAS1R1 | |
| SCHEMBL26515 | 0.88 | HPGD (0.61) | NT5ETGM2HPGDTAS1R3TAS1R1 | |
| SCHEMBL16198946 | 0.88 | HPGD (0.61) | NT5ETGM2HPGDTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | NT5E 1372/4885TGM2 3107/4885ADORA1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.